Shanghai ChemPartner Plans Reverse Merger with China's Quantum

03:07 EDT 21 Jun 2017 | ChinaBio Today

ShangPharma will merge its Shanghai ChemPartner division, which includes all of the company's CRO/CMO operations, into Quantum Hi-Tech China Biological. The transaction, a reverse merger, allows ChemPartner access to China's capital markets, rather than spending years waiting for China IPO approval. ShangPharma said ChemPartner will continue to operate as a stand-alone company, even after the merger. Quantum, which is listed on the Shenzhen exchange with a market capitalization of $1.2 billion, produces fructooligosaccharide products as a probiotic for nutritional snacks. Specific terms, including ChemPartner's merger valuation, were not disclosed. More details....

Stock Symbol: (SZE: 300149)

Share this with colleagues:  

Original Article: Shanghai ChemPartner Plans Reverse Merger with China's Quantum


More From BioPortfolio on "Shanghai ChemPartner Plans Reverse Merger with China's Quantum"

Quick Search


Relevant Topics

Clinical Research Organization
Contract Research Organization (CRO) provide research services outsourced on a contract basis to the pharmaceutical, biotechnology, healthcare and medical device industries: biopharmaceutical development biologic assay development commercial...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...